Trial reportEuropean journal of cancer (Oxford, England : 1990)2017
The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Trial report in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06132542 (Autologous Adipose Derived Mesenchymal Stromal Cell Transplantation in Patients With Idiopathic or Drug Induced Premature Ovarian Failure), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Autologous Adipose Derived Mesenchymal Stromal Cell Transplantation in Patients With Idiopathic or Drug Induced Premature Ovarian Failure
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Recovery of ovarian function after chemotherapy in premenopausal women with breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).Annals of oncology : official journal of the European Society for Medical Oncology · 2026Trial
- Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.Journal of the National Cancer Institute · 2025Trial
- Ovarian reserve in premenopausal women with breast cancer.Breast (Edinburgh, Scotland) · 2022Trial
- Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.The Lancet. Oncology · 2018Trial
- Algorithmic Prognostication in Female Oncofertility Counseling: Ethical Challenges of Bias, Autonomy, and Predictive Uncertainty.Healthcare (Basel, Switzerland) · 2026Review
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- Anti-Müllerian hormone, progesterone, and estrogen at breeding season onset and their association with reproductive performance in multiparous ewes.Frontiers in endocrinology · 2026Article
- Ovarian Escape in Hormone Receptor-Positive Breast Cancer: Mechanisms, Risk Factors, Clinical Consequences, and Management Strategies.Breast cancer (Dove Medical Press) · 2026Review
- Development of a Machine Learning Model for Predicting Treatment-Related Amenorrhea in Young Women with Breast Cancer.Bioengineering (Basel, Switzerland) · 2025Article
- Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.Geburtshilfe und Frauenheilkunde · 2025Article
- Age and serum anti-Müllerian hormone levels as predictors of time to return of menses after chemotherapy.Reproduction & fertility · 2025Article
- Clinical practice guideline for female fertility preservation.Frontiers in medicine · 2025Article
- Molecular Mechanisms Determining Mammalian Oocyte Quality with the Treatment of Cancer Therapy.Advances in anatomy, embryology, and cell biology · 2024Review
- The roles of anti-Müllerian hormone in breast cancer.Endocrine-related cancer · 2023Review
- A prospective longitudinal analysis of the predictors of amenorrhea after breast cancer chemotherapy: Impact of BRCA pathogenic variants.Cancer medicine · 2023Article
- Effect of actinomycin D on ovarian reserve in low-risk gestational trophoblastic neoplasia.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Review
- Premature Ovarian Insufficiency.Current opinion in endocrine and metabolic research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
aimChemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy.
methodsData from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed. Women were assessed for premature ovarian insufficiency (POI: amenorrhoea with elevated follicle-stimulating hormone (FSH)) at 24 months after diagnosis. The accuracy of AMH for the diagnosis of POI and its prediction from measurement at the end of chemotherapy was calculated.
resultsAMH below the level of detection showed good diagnostic accuracy for POI at 24 months (n = 73) with receiver operating characteristic (ROC) area under the curve of 0.86, sensitivity 1.0 and specificity 0.73 at the assay limit of detection. In women aged >40 at diagnosis who did not receive goserelin, AMH measured at end of chemotherapy also gave good prediction of POI at 24 months (area under the curve (AUC) 0.89 95% CI 0.75-1.0, n = 32), with sensitivity 0.91, specificity 0.82, diagnostic odds ratio (DOR) 42.8. FSH gave slightly lower AUC, and specificity was low at 0.55. Age but not tamoxifen impacted on AMH levels.
conclusionUsing this sensitive AMH assay, the finding of an undetectable AMH level in women aged >40 at the end of chemotherapy for eBC gave a good prediction that ovarian function would not return. This may allow alterations in post-chemotherapy endocrine management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.